FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002710366> ?p ?o ?g. }

• W3002710366 abstract "Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation.To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (up to April 2017); this register is compiled by systematic searches of major resources (including AMED, BIOSIS CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings. There are no language, date, document type, or publication status limitations for inclusion of records into the register.Randomised controlled trials (RCTs) comparing rapid use of risperidone and other drugs, combinations of drugs or placebo for people exhibiting aggression or agitation (or both) thought to be due to psychosis.We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all with 95% confidence intervals (CI) and used a fixed-effect model. We assessed risk of bias for the included studies and used the GRADE approach to produce a 'Summary of findings' tables.The review now contains data from nine trials (total n = 582) reporting on five comparisons. Due to risk of bias, small size of trials, indirectness of outcome measures and a paucity of investigated and reported 'pragmatic' outcomes, evidence was graded as very-low quality. None of the included studies provided useable data on our primary outcome 'tranquillisation or asleep' by 30 minutes, repeated need for tranquillisation or any economic outcomes. Data were available for our other main outcomes of agitation or aggression, needing restraint, and incidence of adverse effects.Risperidone versus haloperidol (up to 24 hours follow-up)For the outcome, specific behaviour - agitation, no clear difference was found between risperidone and haloperidol in terms of efficacy, measured as at least 50% reduction in the Positive and Negative Syndrome Scale - Psychotic Agitation Sub-score (PANSS-PAS) (RR 1.04, 95% CI 0.86 to 1.26; participants = 124; studies = 1; very low-quality evidence) and no effect was observed for need to use restraints (RR 2.00, 95% CI 0.43 to 9.21; participants = 28; studies = 1; very low-quality evidence). Incidence of adverse effects was similar between treatment groups (RR 0.94, 95% CI 0.54 to 1.66; participants = 124; studies = 1; very low-quality evidence).Risperidone versus olanzapineOne small trial (n = 29) reported useable data for the comparison risperidone versus olanzapine. No effect was observed for agitation measured as PANSS-PAS endpoint score at two hours (MD 2.50, 95% CI -2.46 to 7.46; very low-quality evidence); need to use restraints at four days (RR 1.43, 95% CI 0.39 to 5.28; very-low quality evidence); specific movement disorders measured as Behavioural Activity Rating Scale (BARS) endpoint score at four days (MD 0.20, 95% CI -0.43 to 0.83; very low-quality evidence).Risperidone versus quetiapineOne trial reported (n = 40) useable data for the comparison risperidone versus quetiapine. Aggression was measured using the Modified Overt Aggression Scale (MOAS) endpoint score at two weeks. A clear difference, favouring quetiapine was observed (MD 1.80, 95% CI 0.20 to 3.40; very-low quality evidence). No evidence of a difference between treatment groups could be observed for incidence of akathisia after 24 hours (RR 1.67, 95% CI 0.46 to 6.06; very low-quality evidence). Two participants allocated to risperidone and one allocated to quetiapine experienced myocardial ischaemia during the trial.Risperidone versus risperidone + oxcarbazepineOne trial (n = 68) measured agitation using the Positive and Negative Syndrome Scale - Excited Component.(PANSS-EC) endpoint score and found a clear difference, favouring the combination treatment at one week (MD 2.70, 95% CI 0.42 to 4.98; very low-quality evidence), but no effect was observed for global state using Clinical Global Impression - Improvement (CGI-I) endpoint score at one week (MD -0.20, 95% CI -0.61 to 0.21; very-low quality evidence). Incidence of extrapyramidal symptoms after 24 hours was similar between treatment groups (RR 1.59, 95% CI 0.49 to 5.14; very-low quality evidence).Risperidone versus risperidone + valproic acidTwo trials compared risperidone with a combination of risperidone plus valproic acid. No clear differences between the treatment groups were observed for aggression (MOAS endpoint score at three days: MD 1.07, 95% CI -0.20 to 2.34; participants = 54; studies = 1; very low-quality evidence) or incidence of akathisia after 24 hours: RR 0.75, 95% CI 0.28 to 2.03; participants = 122; studies = 2; very low-quality evidence).Overall, results for the main outcomes show no real effect for risperidone. The only data available for use in this review are from nine under-sampled trials and the evidence available is of very low quality. This casts uncertainty on the role of risperidone in rapid tranquillisation for people with psychosis-induced aggression. High-quality pragmatic RCTs are feasible and are needed before clear recommendations can be drawn on the use of risperidone for psychosis-induced aggression or agitation." @default.
• W3002710366 created "2020-01-30" @default.
• W3002710366 creator A5002151983 @default.
• W3002710366 creator A5047521970 @default.
• W3002710366 creator A5055401991 @default.
• W3002710366 creator A5076490400 @default.
• W3002710366 creator A5077527200 @default.
• W3002710366 creator A5085074957 @default.
• W3002710366 date "2018-04-10" @default.
• W3002710366 modified "2023-10-18" @default.
• W3002710366 title "Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)" @default.
• W3002710366 cites W1510018163 @default.
• W3002710366 cites W1517837731 @default.
• W3002710366 cites W1533806909 @default.
• W3002710366 cites W1540802235 @default.
• W3002710366 cites W1551675370 @default.
• W3002710366 cites W1554704723 @default.
• W3002710366 cites W1556485502 @default.
• W3002710366 cites W1591259115 @default.
• W3002710366 cites W1686153379 @default.
• W3002710366 cites W1758155888 @default.
• W3002710366 cites W1759768202 @default.
• W3002710366 cites W1833357926 @default.
• W3002710366 cites W1930750863 @default.
• W3002710366 cites W1930770730 @default.
• W3002710366 cites W1931585301 @default.
• W3002710366 cites W1948712038 @default.
• W3002710366 cites W1954888178 @default.
• W3002710366 cites W1964162160 @default.
• W3002710366 cites W1964936180 @default.
• W3002710366 cites W1966576232 @default.
• W3002710366 cites W1975916217 @default.
• W3002710366 cites W1976178155 @default.
• W3002710366 cites W1976791378 @default.
• W3002710366 cites W1977185679 @default.
• W3002710366 cites W1978040764 @default.
• W3002710366 cites W1979819977 @default.
• W3002710366 cites W1982197618 @default.
• W3002710366 cites W1983133139 @default.
• W3002710366 cites W1983183586 @default.
• W3002710366 cites W1985313354 @default.
• W3002710366 cites W1992857340 @default.
• W3002710366 cites W1993190814 @default.
• W3002710366 cites W1993818042 @default.
• W3002710366 cites W1996014577 @default.
• W3002710366 cites W1997108408 @default.
• W3002710366 cites W1997673117 @default.
• W3002710366 cites W1999689270 @default.
• W3002710366 cites W2000227317 @default.
• W3002710366 cites W2007001227 @default.
• W3002710366 cites W2009087216 @default.
• W3002710366 cites W2009475017 @default.
• W3002710366 cites W2015333849 @default.
• W3002710366 cites W2020844317 @default.
• W3002710366 cites W2023839473 @default.
• W3002710366 cites W2032448955 @default.
• W3002710366 cites W2032712358 @default.
• W3002710366 cites W2032926950 @default.
• W3002710366 cites W2035864316 @default.
• W3002710366 cites W2038179898 @default.
• W3002710366 cites W2043437956 @default.
• W3002710366 cites W2046391772 @default.
• W3002710366 cites W2058874144 @default.
• W3002710366 cites W2059038338 @default.
• W3002710366 cites W2059503302 @default.
• W3002710366 cites W2062495017 @default.
• W3002710366 cites W2066448639 @default.
• W3002710366 cites W2075153233 @default.
• W3002710366 cites W2076071225 @default.
• W3002710366 cites W2078819444 @default.
• W3002710366 cites W2080939138 @default.
• W3002710366 cites W2081607815 @default.
• W3002710366 cites W2083850795 @default.
• W3002710366 cites W2084101383 @default.
• W3002710366 cites W2089396960 @default.
• W3002710366 cites W2092169773 @default.
• W3002710366 cites W2097768453 @default.
• W3002710366 cites W2106848296 @default.
• W3002710366 cites W2107962758 @default.
• W3002710366 cites W2115058221 @default.
• W3002710366 cites W2118204514 @default.
• W3002710366 cites W2119527374 @default.
• W3002710366 cites W2120647667 @default.
• W3002710366 cites W2126930838 @default.
• W3002710366 cites W2128659393 @default.
• W3002710366 cites W2130235475 @default.
• W3002710366 cites W2135029321 @default.
• W3002710366 cites W2139514592 @default.
• W3002710366 cites W2142842754 @default.
• W3002710366 cites W2147776349 @default.
• W3002710366 cites W2149839740 @default.
• W3002710366 cites W2152240392 @default.
• W3002710366 cites W2157823046 @default.
• W3002710366 cites W2163467563 @default.
• W3002710366 cites W2165379748 @default.
• W3002710366 cites W2166157732 @default.
• W3002710366 cites W2166256285 @default.
• W3002710366 cites W2166346439 @default.
• W3002710366 cites W2168505756 @default.
• W3002710366 cites W2182969441 @default.

• next